{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Small+Cell+Neuroendocrine+Carcinoma&page=19", "query": { "condition": "Small Cell Neuroendocrine Carcinoma", "page": 19 }, "page_size": 10 }, "pagination": { "page": 19, "page_size": 10, "total_count": 743, "total_pages": 75, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Small+Cell+Neuroendocrine+Carcinoma&page=20&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Small+Cell+Neuroendocrine+Carcinoma&page=18&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T01:57:46.910Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06732401", "title": "Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Non-Small Cell Carcinoma", "Stage II Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Ceralasertib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Echocardiography Test", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 630, "start_date": "2025-08-07", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-14T01:57:46.910Z", "location_count": 192, "location_summary": "Jonesboro, Arkansas • Beverly Hills, California • Los Angeles, California + 163 more", "locations": [ { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Tarzana", "state": "California" }, { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06732401" }, { "nct_id": "NCT04106167", "title": "Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Advanced Solid Tumor", "Lymphoma", "Gastric Cancer", "Colorectal Cancer", "Head and Neck Cancer", "Squamous Cell Carcinoma", "EGFR Positive Solid Tumor", "HER2-positive Breast Cancer", "Hepatocellular Carcinoma", "Small-cell Lung Cancer", "Renal Cell Carcinoma", "Pancreas Cancer", "Melanoma", "NSCLC", "Urothelial Carcinoma", "Cervical Cancer", "Microsatellite Instability", "Merkel Cell Carcinoma" ], "interventions": [ { "name": "Allogeneic natural killer (NK) cell", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2019-06-11", "completion_date": "2023-08-11", "has_results": false, "last_update_posted_date": "2023-09-21", "last_synced_at": "2026-10-14T01:57:46.910Z", "location_count": 4, "location_summary": "San Diego, California • Minneapolis, Minnesota • Hackensack, New Jersey + 1 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04106167" }, { "nct_id": "NCT05642572", "title": "Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Lung Non-Small Cell Carcinoma", "Stage IV Lung Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Capmatinib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Osimertinib", "type": "DRUG" }, { "name": "Ramucirumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2023-05-05", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-10-14T01:57:46.910Z", "location_count": 454, "location_summary": "Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 360 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Saraland", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT05642572" }, { "nct_id": "NCT03811002", "title": "Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Limited Stage Lung Small Cell Carcinoma", "Stage I Lung Cancer AJCC v8", "Stage II Lung Cancer AJCC v8", "Stage III Lung Cancer AJCC v8" ], "interventions": [ { "name": "3-Dimensional Conformal Radiation Therapy", "type": "RADIATION" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "RADIATION", "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 544, "start_date": "2019-07-26", "completion_date": "2029-02-21", "has_results": true, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-10-14T01:57:46.910Z", "location_count": 532, "location_summary": "Birmingham, Alabama • Fairbanks, Alaska • Gilbert, Arizona + 400 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fairbanks", "state": "Alaska" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03811002" }, { "nct_id": "NCT06518057", "title": "Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Metastatic Breast Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Neoplasm in the Leptomeninges", "Stage IV Lung Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Electronic Health Record Review", "type": "OTHER" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Proton Beam Craniospinal Irradiation", "type": "RADIATION" }, { "name": "Survey Administration", "type": "OTHER" }, { "name": "Volume Modulated Arc Therapy", "type": "RADIATION" }, { "name": "Hippocampal-Avoidance Craniospinal Irradiation", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "OTHER", "RADIATION" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2025-03-03", "completion_date": "2028-07-01", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-10-14T01:57:46.910Z", "location_count": 3, "location_summary": "San Francisco, California • New York, New York • Seattle, Washington", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06518057" }, { "nct_id": "NCT00126581", "title": "Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Adenocarcinoma", "Lung Adenosquamous Carcinoma", "Malignant Pericardial Effusion", "Malignant Pleural Effusion", "Minimally Invasive Lung Adenocarcinoma", "Stage IIIB Lung Non-Small Cell Cancer AJCC v7", "Stage IV Lung Non-Small Cell Cancer AJCC v7" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Erlotinib Hydrochloride", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 188, "start_date": "2005-08-15", "completion_date": "2017-11-28", "has_results": true, "last_update_posted_date": "2019-08-07", "last_synced_at": "2026-10-14T01:57:46.910Z", "location_count": 96, "location_summary": "Castro Valley, California • Emeryville, California • Fremont, California + 68 more", "locations": [ { "city": "Castro Valley", "state": "California" }, { "city": "Castro Valley", "state": "California" }, { "city": "Castro Valley", "state": "California" }, { "city": "Emeryville", "state": "California" }, { "city": "Fremont", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00126581" }, { "nct_id": "NCT05652686", "title": "A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Small Cell Lung Cancer (SCLC)", "Large Cell Neuroendocrine Cancer (LCNEC)", "Neuroendocrine Prostate Cancer (NEPC)", "Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)", "Neuroendocrine Carcinomas (NEC)", "Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)" ], "interventions": [ { "name": "Peluntamig (PT217)", "type": "DRUG" }, { "name": "Carboplatin + Etoposide", "type": "DRUG" }, { "name": "Paclitaxel.", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Lurbinectedin", "type": "DRUG" }, { "name": "Irinotecan (drug)", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Phanes Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 203, "start_date": "2023-09-05", "completion_date": "2028-08", "has_results": false, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-10-14T01:57:46.910Z", "location_count": 15, "location_summary": "Duarte, California • Los Angeles, California • Denver, Colorado + 11 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05652686" }, { "nct_id": "NCT06781983", "title": "Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced or Metastatic Solid Tumors" ], "interventions": [ { "name": "IPH4502", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Innate Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 145, "start_date": "2025-01-24", "completion_date": "2029-04", "has_results": false, "last_update_posted_date": "2026-07-27", "last_synced_at": "2026-10-14T01:57:46.910Z", "location_count": 5, "location_summary": "Boston, Massachusetts • Hackensack, New Jersey • New York, New York + 2 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Dallas", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06781983" }, { "nct_id": "NCT02489903", "title": "RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Small Cell Carcinoma", "Carcinoma, Non-Small-Cell Lung", "Neuroendocrine Tumors", "Ovarian Epithelial Cancer" ], "interventions": [ { "name": "RRx-001", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" }, { "name": "Doxil", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Taxane", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab-Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EpicentRx, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 139, "start_date": "2015-06", "completion_date": "2021-12-06", "has_results": true, "last_update_posted_date": "2025-03-17", "last_synced_at": "2026-10-14T01:57:46.910Z", "location_count": 10, "location_summary": "Palo Alto, California • West Haven, Connecticut • South Bend, Indiana + 7 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "West Haven", "state": "Connecticut" }, { "city": "South Bend", "state": "Indiana" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02489903" }, { "nct_id": "NCT02164461", "title": "Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Effects of Immunotherapy", "Metastatic/Recurrent Cervical Cancer", "Cervical Adenocarcinoma", "Cervical Adenosquamous Cell Carcinoma", "Cervical Squamous Cell Carcinoma", "Cervical Small Cell Carcinoma", "Stage III Cervical Cancer", "Stage IVA Cervical Cancer", "Stage IVB Cervical Cancer" ], "interventions": [ { "name": "Axalimogene filolisbac", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Advaxis, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 12, "start_date": "2015-03-04", "completion_date": "2017-03-08", "has_results": true, "last_update_posted_date": "2024-05-20", "last_synced_at": "2026-10-14T01:57:46.910Z", "location_count": 2, "location_summary": "Augusta, Georgia • Charlottesville, Virginia", "locations": [ { "city": "Augusta", "state": "Georgia" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02164461" } ] }